Santhera Pharmaceuticals Holding AG (SPHDF)
11.70
0.00 (0.00%)
USD |
OTCM |
Jun 26, 16:00
Santhera Pharmaceuticals Enterprise Value: 121.22M for June 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
June 26, 2024 | 121.22M |
June 25, 2024 | 121.22M |
June 24, 2024 | 121.22M |
June 21, 2024 | 121.22M |
June 20, 2024 | 121.22M |
June 18, 2024 | 121.22M |
June 17, 2024 | 121.22M |
June 14, 2024 | 121.22M |
June 13, 2024 | 121.22M |
June 12, 2024 | 121.22M |
June 11, 2024 | 121.22M |
June 10, 2024 | 121.22M |
June 07, 2024 | 121.22M |
June 06, 2024 | 121.22M |
June 05, 2024 | 121.22M |
June 04, 2024 | 121.22M |
June 03, 2024 | 121.22M |
May 31, 2024 | 121.22M |
May 30, 2024 | 121.22M |
May 29, 2024 | 121.22M |
May 28, 2024 | 121.22M |
May 24, 2024 | 121.22M |
May 23, 2024 | 121.22M |
May 22, 2024 | 121.22M |
May 21, 2024 | 121.22M |
Date | Value |
---|---|
May 20, 2024 | 121.22M |
May 17, 2024 | 121.22M |
May 16, 2024 | 121.22M |
May 15, 2024 | 121.22M |
May 14, 2024 | 121.22M |
May 13, 2024 | 121.22M |
May 10, 2024 | 121.22M |
May 09, 2024 | 121.22M |
May 08, 2024 | 121.22M |
May 07, 2024 | 121.22M |
May 06, 2024 | 121.22M |
May 03, 2024 | 121.22M |
May 02, 2024 | 121.22M |
May 01, 2024 | 121.22M |
April 30, 2024 | 121.18M |
April 29, 2024 | 121.18M |
April 26, 2024 | 121.18M |
April 25, 2024 | 121.18M |
April 24, 2024 | 121.18M |
April 23, 2024 | 121.18M |
April 22, 2024 | 121.18M |
April 19, 2024 | 121.18M |
April 18, 2024 | 121.18M |
April 17, 2024 | 121.18M |
April 16, 2024 | 121.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
59.84M
Minimum
Nov 11 2021
206.87M
Maximum
Aug 27 2019
115.11M
Average
120.73M
Median
Jan 08 2021
Enterprise Value Benchmarks
AC Immune SA | 276.46M |
CRISPR Therapeutics AG | 2.701B |
Addex Therapeutics Ltd | 6.723M |
NLS Pharmaceutics Ltd | 8.658M |
Molecular Partners AG | 49.74M |
Enterprise Value Related Metrics
Earnings Yield | 48.60% |
Operating Earnings Yield | 45.42% |
Normalized Earnings Yield | 25.69 |